First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect

Inclusion Criteria:

- Subject must be 18 to 65 years of age inclusive, at the time of signing the informed
consent.

- Subjects who are overtly healthy as determined by medical evaluation including medical
history, physical examination, laboratory tests, and cardiac monitoring. A subject
with a clinical abnormality or laboratory parameter(s) not specifically listed in the
exclusion or exclusion criteria that is outside the reference range for the population
being studied may be included only if the investigator, in consultation with the
Medical Monitor, agree and document that the finding is unlikely to introduce
additional risk factors and will not interfere with the study procedures.

- Subjects with Body weight >=50.0 kilograms (Kg) (110 lbs.) and body mass index (BMI)
within the range 18.5 to 31.0 kilograms per square meter (inclusive).

- Only male subjects are eligible for this study. Contraceptive use should be consistent
with local regulations regarding the methods of contraception for those participating
in clinical studies.

- Male subjects are eligible to participate if they agree to the following during the
their entire enrolment in the study plus an additional 5 days or 5 terminal half-lives
(whichever is longer): Refrain from donating sperm plus either be abstinent from
sexual intercourse as their preferred and usual lifestyle (abstinent on a long term
and persistent basis) and agree to remain abstinent or must agree to use
contraception/barrier (female partner to use an additional highly effective
contraceptive method with a failure rate of <1% per year)

- Subjects must be capable of giving signed informed consent

Exclusion Criteria:

- Subjects are excluded from the study if they have history or presence of
cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine,
hematological, or neurological disorders capable of significantly altering the
absorption, metabolism, or elimination of drugs; constituting a risk when taking the
study intervention; or interfering with the interpretation of data.

- Subjects are excluded from the study if they have any clinically significant abnormal
vital signs

- Subjects are excluded from the study if they have Lymphoma, leukemia, or any
malignancy within the past 5 years except for basal cell or squamous epithelial
carcinomas of the skin that have been resected with no evidence of metastatic disease
for 3 years

- Subjects are excluded from the study if they have ALT >1.5 times upper limit of normal
(ULN)

- Subjects are excluded from the study if Bilirubin >1.5 times ULN (isolated bilirubin
>1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)

- Subjects are excluded from the study if they have current or chronic history of liver
disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's
syndrome or asymptomatic gallstones)

- Subjects are excluded from the study if they have QTc >450 milliseconds

- Subjects who are unable to refrain from the use of prescription or non-prescription
drugs, including aspirin, Non-steroidal Anti-inflammatory Drugs (NSAIDs), vitamins,
herbal and dietary supplements (including St John's Wort) within 10 days prior to the
first dose of study medication.

- In cases, where participation in the study would result in loss of blood or blood
products in excess of 500 milliliter (mL) within 56 days

- Subjects with exposure to more than 4 new chemical entities within 12 months prior to
the first dosing day.

- Subjects with current enrolment or past participation within the last 30 days before
signing of consent in this or any other clinical study involving an investigational
study intervention or any other type of medical research.

- Subjects with presence of Hepatitis B surface antigen (HBsAg) at screening.

- Subjects with Positive Hepatitis C antibody test result at screening. Subjects with
positive Hepatitis C antibody due to prior resolved disease can be enrolled, only if a
confirmatory negative Hepatitis C ribonucleic acid (RNA) test is obtained.

- Subjects with Positive Hepatitis C Ribonucleic acid (RNA) test result at screening or
within 3 months prior to first dose of study intervention

- Subjects with positive pre-study drug/alcohol screen

- Subjects with positive human immunodeficiency virus (HIV) antibody test

- Subjects with regular use of known drugs of abuse or positive urine drug test at
screening or each in-house admission to the clinical research unit

- Subjects with regular alcohol consumption within 6 months prior to screening and 5
days prior to admission defined as: An average weekly intake of > 14 units for males.
One unit is equivalent to 8 gram of alcohol: a half-pint (Approximately 240 mL) of
beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of 80 proof distilled spirits

- Subjects with positive urinary cotinine test indicative of smoking history at
screening or each in-house admission to the clinical research unit or regular use of
tobacco- or nicotine-containing products (e.g. nicotine patches or vaporizing devices)
within 6 months prior to screening

- Subjects with sensitivity to any of the study interventions, or components thereof, or
drug or other allergy that, in the opinion of the investigator or medical monitor,
contraindicates participation in the study.